KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShort-Term Debt issuances
Ratios

Astrazeneca (AZN) Leases (2019 - 2025)

Historic Leases for Astrazeneca (AZN) over the last 7 years, with Q4 2025 value amounting to $1.7 billion.

  • Astrazeneca's Leases rose 2480.29% to $1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 2480.29%. This contributed to the annual value of $1.7 billion for FY2025, which is 2480.29% up from last year.
  • Astrazeneca's Leases amounted to $1.7 billion in Q4 2025, which was up 2480.29% from $1.7 billion recorded in Q3 2025.
  • Astrazeneca's Leases' 5-year high stood at $1.7 billion during Q4 2025, with a 5-year trough of $660.0 million in Q1 2021.
  • Its 5-year average for Leases is $1.1 billion, with a median of $982.5 million in 2021.
  • As far as peak fluctuations go, Astrazeneca's Leases surged by 9340.0% in 2021, and later tumbled by 770.04% in 2022.
  • Over the past 5 years, Astrazeneca's Leases (Quarter) stood at $988.0 million in 2021, then decreased by 4.66% to $942.0 million in 2022, then increased by 16.77% to $1.1 billion in 2023, then rose by 26.82% to $1.4 billion in 2024, then increased by 24.8% to $1.7 billion in 2025.
  • Its Leases stands at $1.7 billion for Q4 2025, versus $1.7 billion for Q3 2025 and $1.6 billion for Q2 2025.